Oxford

The University of Oxford has launched a Phase 1 trial of a multivalent Ebola vaccine candidate targeting both the Zaire and Sudan strains of the filovirus, the university announced last week.

The ChAdOx1 biEBOV vaccine uses the same adenovirus vector platform as the AstraZeneca/Oxford Covid-19 shot, whose storage conditions are “amenable to use in the developing world,” the trial’s chief investigator noted. By contrast, Merck’s Ebola vaccine, Ervebo, requires ultracold storage.

University of Oxford researchers on Wednesday launched a Phase 1 trial of an adenoviral-vectored vaccine candidate for human plague. Forty healthy adults ages 18-55 will receive the new shot, which is based on the same ChAdOx1 platform used for the AstraZeneca/Oxford Covid-19 vaccine, according to a press release from the university.

Mentions:

The state of the hunt:

European, South African and U.S. regulators cleared J&J’s single-dose vaccine for resumed use.
  Pfizer/BioNTech’s vaccine showed 85% effectiveness against any infection—symptomatic or not—in a 23,000-participant British study of health workers, published in The Lancet.
  India authorized a Zydus Cadila hepatitis therapy for emergency use against Covid-19.

 

Vaccines


Approved or authorized vaccines
   
A U.S…

The state of the hunt:

Novavax’s protein-based vaccine candidate demonstrated 89.3% efficacy in a UK Phase 3 trial.
  J&J/Janssen’s single-dose vaccine was 66% effective against moderate to severe disease in Phase 3.
  Vaccines from J&J, Moderna, Novavax and Pfizer/BioNTech appear less effective against the SARS-CoV-2 variant first identified in South Africa.

 

Vaccines


Approved or authorized vaccines

AstraZeneca’s vaccine…

The state of the hunt:

Novavax’s protein-based vaccine candidate demonstrated 89.3% efficacy in a UK Phase 3 trial.
  J&J/Janssen’s single-dose vaccine was 66% effective against moderate to severe disease in Phase 3.
  Vaccines from J&J, Moderna, Novavax and Pfizer/BioNTech appear less effective against the SARS-CoV-2 variant first identified in South Africa.

 

Vaccines


Approved or authorized vaccines

AstraZeneca/Oxford’s…

The state of the hunt:

COVAX has inked a deal for up to 40 million doses of Pfizer/BioNTech’s vaccine.
  India launched its mass vaccination campaign against Covid-19.
  China and India are both giving away vaccine doses to their neighbors.

 

Vaccines


Approved or authorized vaccines
 
China’s Sinovac jab more effective using three-week interval: A silver lining has emerged to last week’s middling news from the Butantan Institute’s…

Britain’s University of Oxford announced Tuesday a $136 million donation from UK-based chemical giant Ineos to establish a research institute to combat antimicrobial resistance.

The new Ineos Oxford Institute for AMR Research will unite the university’s chemistry and zoology departments in an effort to design new human drugs and “novel antimicrobials just for animals,” the press release said.

Mentions:

The state of the hunt:

India inked vaccine supply deals with Bharat Biotech and SII.
  BioNTech upped its 2021 production target for Comirnaty to 2 billion doses—but the Pfizer/BioNTech vaccine faced near-term production slowdowns and delivery lags.
  An African Union-backed supply initiative locked up 270 million vaccine doses for the continent.

 

Vaccines


Approved or authorized vaccines

Sinovac’s inactivated jab notched its first…

The state of the hunt:

The AstraZeneca/Oxford vaccine secured its first authorizations.
  Novavax launched a 30,000-participant North American Phase 3 trial for its recombinant vaccine.
  CNBG claimed 79% efficacy for the inactivated jab from its Beijing subsidiary but provided scant data.

 

Vaccines


Approved or authorized vaccines
 
UK authorizes AstraZeneca/Oxford jab: Britain’s Medicines and Healthcare products Regulatory Agency…

The state of the hunt:

Moderna’s became the second Covid-19 vaccine to receive U.S. FDA Emergency Use Authorization.
  COVAX has secured nearly 2 billion doses of vaccines but faces a “very high” failure risk, according to Reuters.
  Canada, Saudi Arabia and the United States have begun immunization campaigns using Pfizer/BioNTech’s jab.

 

Vaccines


Approved or authorized vaccines
 
The U.S. FDA granted Emergency Use Authorization (EUA…